Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.67 |
| ▸ | FAAH | O00519 | 3/20 | 0.65 |
| ▸ | CNR1 | P21554 | 4/20 | 0.63 |
| ▸ | CNR2 | P34972 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.55 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10034055 | 1.00 | EPHX2 (0.67) | EPHX2FAAHCNR1CNR2KDM4E | |
| Hydrochloric Acid SCHEMBL28383398 | 0.99 | EPHX2 (0.65) | EPHX2FAAHCNR1CNR2KDM4E | |
| SCHEMBL17453301 | 0.98 | EPHX2 (0.64) | EPHX2FAAHCNR1CNR2KDM4E | |
| SCHEMBL10108760 | 0.95 | EPHX2 (0.59) | EPHX2FAAHCNR1CNR2KDM4E | |
| SCHEMBL10108780 | 0.93 | EPHX2 (0.67) | EPHX2FAAHCNR1CNR2KDM4E | |
| Miramistin Ion SCHEMBL2238282 | 0.93 | DNM1 (0.62) | EPHX2FAAHCNR1CNR2DNM1 | |
| SCHEMBL10034064 | 0.93 | DNM1 (0.62) | EPHX2FAAHCNR1CNR2DNM1 | |
| SCHEMBL11305761 | 0.93 | DNM1 (0.62) | EPHX2FAAHCNR1CNR2DNM1 | |
| Miramistin Ion SCHEMBL23922700 | 0.92 | MEN1 (0.62) | EPHX2FAAHCNR1CNR2DNM1 | |
| Miramistin Ion SCHEMBL2236560 | 0.92 | MEN1 (0.63) | EPHX2FAAHCNR1CNR2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815780-B2 | Quaternized fatty amines, amidoamines and their derivatives from natural oil | STEPAN COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170211016-A1 | SYNERGISTIC SURFACTANT BLENDS | STEPAN CO (US) | 2017-07-27 | — | — | US | disclosed |
| US-9688944-B2 | Synergistic surfactant blends | STEPAN COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9416099-B2 | Quaternized fatty amines, amidoamines and their derivatives from natural oil metathesis | STEPAN COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-20160024003-A1 | QUATERNIZED FATTY AMINES, AMIDOAMINES AND THEIR DERIVATIVES FROM NATURAL OIL METATHESIS | STEPAN CO (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160016898-A1 | QUATERNIZED FATTY AMINES, AMIDOAMINES AND THEIR DERIVATIVES FROM NATURAL OIL METATHESIS | STEPHAN COMPANY (US) | 2016-01-21 | — | — | US | disclosed |
| US-9193936-B2 | Quaternized fatty amines, amidoamines and their derivatives from natural oil metathesis | STEPAN COMPANY (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150094383-A1 | SYNERGISTIC SURFACTANT BLENDS | STEPAN CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130225409-A1 | QUATERNIZED FATTY AMINES, AMIDOAMINES AND THEIR DERIVATIVES FROM NATURAL OIL METATHESIS | STEPAN COMPANY (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2012061098-A1 | QUATERNIZED FATTY AMINES, AMIDOAMINES, AND THEIR DERIVATIVES FROM NATURAL OIL METATHESIS | STEPAN COMPANY (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225409-A1 | QUATERNIZED FATTY AMINES, AMIDOAMINES AND THEIR DERIVATIVES FROM NATURAL OIL METATHESIS | ABHD5, ABHD6, SGMS1 | EPHX2 2113/4885FAAH 77/4885CNR1 935/4885 |
| US-20150094383-A1 | SYNERGISTIC SURFACTANT BLENDS | HHAT, AADAT, SQLE | EPHX2 3237/4885FAAH 572/4885CNR1 1379/4885 |
| US-20160024003-A1 | QUATERNIZED FATTY AMINES, AMIDOAMINES AND THEIR DERIVATIVES FROM NATURAL OIL METATHESIS | ABHD5, ABHD6, SGMS1 | EPHX2 1904/4885FAAH 90/4885CNR1 1064/4885 |
| US-20160016898-A1 | QUATERNIZED FATTY AMINES, AMIDOAMINES AND THEIR DERIVATIVES FROM NATURAL OIL METATHESIS | ABHD5, ABHD6, SGMS1 | EPHX2 1849/4885FAAH 89/4885CNR1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.